Resumo

MENDOZA PEREZ, Felipe et al. B-cell targeted therapies in Sjogren's syndrome. Rev. mex. cienc. farm [online]. 2014, vol.45, n.4, pp.1-12. ISSN 1870-0195.

Primary Sjogren's syndrome is characterized by infiltration of mononuclear cells of exocrine glands and an activity of lymphocytes B. For a long time thought that the T cells were the primary effector, recent evidence indicates that B cells play an important role in the development of the disease. Conventional therapies do not alter the course of the disease, by which B cells have become attractive as target in therapies, the use of monoclonal antibodies against CD20 (Rituximab), induces a rapid depletion of B cells by which may improve early disease or with extraglandular involvement. There are other molecules with therapeutic possibilities in experimental stage one of these is the blocking of B-cell activating factor.

Palavras-chave : Sjögren's syndrome; B Cells; B cells Therapy; Rituximab; Anti-CD20.